1.Use of artificial intelligence in the management of T1 colorectal cancer: a new tool in the arsenal or is deep learning out of its depth?
James Weiquan LI ; Lai Mun WANG ; Katsuro ICHIMASA ; Kenneth Weicong LIN ; James Chi-Yong NGU ; Tiing Leong ANG
Clinical Endoscopy 2024;57(1):24-35
		                        		
		                        			
		                        			 The field of artificial intelligence is rapidly evolving, and there has been an interest in its use to predict the risk of lymph node metastasis in T1 colorectal cancer. Accurately predicting lymph node invasion may result in fewer patients undergoing unnecessary surgeries; conversely, inadequate assessments will result in suboptimal oncological outcomes. This narrative review aims to summarize the current literature on deep learning for predicting the probability of lymph node metastasis in T1 colorectal cancer, highlighting areas of potential application and barriers that may limit its generalizability and clinical utility. 
		                        		
		                        		
		                        		
		                        	
4.Colonic stenting in acute malignant large bowel obstruction: audit of efficacy and safety in a Singapore tertiary referral centre.
James Weiquan LI ; James Chi-Yong NGU ; Kok Ren LIM ; Shu Wen TAY ; Bochao JIANG ; Ramesh WIJAYA ; Sulaiman YUSOF ; Calvin Jianming ONG ; Andrew Boon EU KWEK ; Tiing Leong ANG
Singapore medical journal 2023;64(10):603-608
		                        		
		                        			INTRODUCTION:
		                        			Acute malignant large bowel obstruction (MBO) occurs in 8%-15% of colorectal cancer patients. Self-expandable metal stents (SEMS) have progressed from a palliative modality to use as bridge to surgery (BTS). We aimed to assess the safety and efficacy of SEMS for MBO in our institution.
		                        		
		                        			METHODS:
		                        			The data of patients undergoing SEMS insertion for MBO were reviewed. Technical success was defined as successful SEMS deployment across tumour without complications. Clinical success was defined as colonic decompression without requiring further surgical intervention. Rates of complications, median time to surgery, types of surgery and rates of recurrence were studied.
		                        		
		                        			RESULTS:
		                        			Seventy-nine patients underwent emergent SEMS placement from September 2013 to February 2020. Their mean age was 68.8 ± 13.8 years and 43 (54%) patients were male. Mean tumour length was 4.2 cm ± 2.2 cm; 89.9% of malignant strictures were located distal to the splenic flexure. Technical and clinical success was 94.9% and 98.7%, respectively. Perforation occurred in 5.1% of patients, with none having stent migration or bleeding. Fifty (63.3%) patients underwent SEMS insertion as BTS. Median time to surgery was 20 (range 6-57) days. Most (82%) patients underwent minimally invasive surgery. Primary anastomosis rate was 98%. Thirty-nine patients had follow-up beyond 1-year posttreatment (median 34 months). Local recurrence and distant metastasis were observed in 4 (10.3%) and 5 (12.8%) patients, respectively.
		                        		
		                        			CONCLUSION
		                        			Insertion of SEMS for acute MBO has high success rates and a good safety profile. Most patients in this audit underwent minimally invasive surgery and primary anastomosis after successful BTS.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Aged
		                        			;
		                        		
		                        			Aged, 80 and over
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Colorectal Neoplasms/pathology*
		                        			;
		                        		
		                        			Singapore
		                        			;
		                        		
		                        			Tertiary Care Centers
		                        			;
		                        		
		                        			Stents/adverse effects*
		                        			;
		                        		
		                        			Intestinal Obstruction/etiology*
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Palliative Care
		                        			
		                        		
		                        	
5.Singapore Medical Journal: reflecting on 2023.
Tiing Leong ANG ; Mahesh CHOOLANI ; Kian Keong POH
Singapore medical journal 2023;64(12):713-713
		                        		
		                        		
		                        		
		                        	
6.Clinical audit of current Helicobacter pylori treatment outcomes in Singapore.
Tiing Leong ANG ; Kim Wei LIM ; Daphne ANG ; Yu Jun WONG ; Malcolm TAN ; Andrew Siang YIH WONG
Singapore medical journal 2022;63(9):503-508
		                        		
		                        			INTRODUCTION:
		                        			H. pylori eradication reduces the risk of gastric malignancies and peptic ulcer disease. First-line therapies include 14-day PAC (proton pump inhibitor [PPI], amoxicillin, clarithromycin) and PBMT (PPI, bismuth, metronidazole, tetracycline). Second-line therapies include 14-day PBMT and PAL (PPI, amoxicillin, levofloxacin). This clinical audit examined current treatment outcomes in Singapore.
		                        		
		                        			METHODS:
		                        			Clinical data of H. pylori-positive patientswho underwent empirical first- and second-line eradication therapies from 1 January 2017 to 31 December 2018 were reviewed. Treatment success was determined by 13C urea breath test performed at least 4 weeks after treatment and 2 weeks off PPI.
		                        		
		                        			RESULTS:
		                        			A total of 963 patients (862 PAC, 36 PMC [PPI, metronidazole, clarithromycin], 18 PBMT, 13 PBAC [PAC with bismuth], 34 others) and 98 patients (62 PMBT, 15 PAL, 21 others) received first-and second-line therapies respectively. A 14-day treatment duration was appropriately prescribed for first- and second-line therapies in 65.2% and 82.7% of patients, respectively. First-line treatment success rates were noted for PAC (seven-day: 76.9%, ten-day: 88.3%, 14-day: 92.0%), PMC (seven-day: 0, ten-day: 75.0%, 14-day: 69.8%), PBMT (ten-day: 100%, 14-day: 87.5%) and PBAC (14-day: 100%). 14-day treatment was superior to seven-day treatment (90.8% vs. 71.4%; P = 0.028). PAC was superior to PMC (P < 0.001) but similar to PBMT (P = 0.518) and PBAC (P = 0.288) in 14-day therapies. 14-day second-line PAL and PBMT had similar efficacy (90.9% vs. 82.4%; P = 0.674).
		                        		
		                        			CONCLUSION
		                        			First-line empirical treatment using PAC, PBMT and PBAC for 14 days had similar efficacy. Success rates for second-line PBMT and PAL were similar.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Helicobacter pylori
		                        			;
		                        		
		                        			Clarithromycin/therapeutic use*
		                        			;
		                        		
		                        			Helicobacter Infections/drug therapy*
		                        			;
		                        		
		                        			Metronidazole/therapeutic use*
		                        			;
		                        		
		                        			Bismuth/therapeutic use*
		                        			;
		                        		
		                        			Singapore
		                        			;
		                        		
		                        			Drug Therapy, Combination
		                        			;
		                        		
		                        			Amoxicillin/therapeutic use*
		                        			;
		                        		
		                        			Proton Pump Inhibitors/therapeutic use*
		                        			;
		                        		
		                        			Anti-Bacterial Agents/therapeutic use*
		                        			;
		                        		
		                        			Treatment Outcome
		                        			;
		                        		
		                        			Clinical Audit
		                        			
		                        		
		                        	
7.Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis.
Bryan Peide CHOO ; George Boon Bee GOH ; Sing Yi CHIA ; Hong Choon OH ; Ngiap Chuan TAN ; Jessica Yi Lyn TAN ; Tiing Leong ANG ; Yong Mong BEE ; Yu Jun WONG
Annals of the Academy of Medicine, Singapore 2022;51(11):686-694
		                        		
		                        			INTRODUCTION:
		                        			The cost-effectiveness of screening asymptomatic non-alcoholic fatty liver disease (NAFLD) patients remains debatable, with current studies assuming lifelong benefits of NAFLD screening while neglecting cardiovascular outcomes. This study aims to assess the cost-effectiveness of NAFLD screening among type 2 diabetes mellitus (T2DM) patients, and to establish a price threshold for NAFLD treatment, when it becomes available.
		                        		
		                        			METHOD:
		                        			A Markov model was constructed comparing 4 screening strategies (versus no screening) to identify NAFLD with advanced fibrosis among T2DM patients: fibrosis-4 (FIB-4), vibration-controlled transient elastography (VCTE), FIB-4 and VCTE (simultaneous), and FIB-4 and VCTE (sequential). Sensitivity analyses and price threshold analyses were performed to assess parameter uncertainties in the results.
		                        		
		                        			RESULTS:
		                        			VCTE was the most cost-effective NAFLD screening strategy (USD24,727/quality-adjusted life year [QALY]), followed by FIB-4 (USD36,800/QALY), when compared to no screening. Probabilistic sensitivity analysis revealed a higher degree of certainty for VCTE as a cost-effective strategy compared to FIB-4 (90.7% versus 73.2%). The duration of expected screening benefit is the most influential variable based on incremental cost-effectiveness ratio tornado analysis. The minimum duration of screening benefit for NAFLD screening to be cost-effective was at least 2.6 years. The annual cost of NAFLD treatment should be less than USD751 for NAFLD screening to be cost-effective.
		                        		
		                        			CONCLUSION
		                        			Both VCTE and FIB-4 are cost-effective NAFLD screening strategies among T2DM patients in Singapore. However, given the lack of access to VCTE at primacy care and potential budget constraints, FIB-4 can also be considered for NAFLD screening among T2DM patients in Singapore.
		                        		
		                        		
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Non-alcoholic Fatty Liver Disease/diagnosis*
		                        			;
		                        		
		                        			Cost-Benefit Analysis
		                        			;
		                        		
		                        			Diabetes Mellitus, Type 2/diagnosis*
		                        			;
		                        		
		                        			Research
		                        			;
		                        		
		                        			Fibrosis
		                        			
		                        		
		                        	
8.Academy of Medicine, Singapore clinical guideline on endoscopic surveillance and management of gastric premalignant lesions.
Vikneswaran NAMASIVAYAM ; Calvin J KOH ; Stephen TSAO ; Jonathan LEE ; Khoon Lin LING ; Christopher KHOR ; Tony LIM ; James Weiquan LI ; Aung Myint OO ; Benjamin C H YIP ; Ikram HUSSAIN ; Tju Siang CHUA ; Bin Chet TOH ; Hock Soo ONG ; Lai Mun WANG ; Jimmy B Y SO ; Ming THE ; Khay Guan YEOH ; Tiing Leong ANG
Annals of the Academy of Medicine, Singapore 2022;51(7):417-435
		                        		
		                        			
		                        			Gastric cancer (GC) has a good prognosis, if detected at an early stage. The intestinal subtype of GC follows a stepwise progression to carcinoma, which is treatable with early detection and intervention using high-quality endoscopy. Premalignant lesions and gastric epithelial polyps are commonly encountered in clinical practice. Surveillance of patients with premalignant gastric lesions may aid in early diagnosis of GC, and thus improve chances of survival. An expert professional workgroup was formed to summarise the current evidence and provide recommendations on the management of patients with gastric premalignant lesions in Singapore. Twenty-five recommendations were made to address screening and surveillance, strategies for detection and management of gastric premalignant lesions, management of gastric epithelial polyps, and pathological reporting of gastric premalignant lesions.
		                        		
		                        		
		                        		
		                        			Adenomatous Polyps
		                        			;
		                        		
		                        			Endoscopy
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Precancerous Conditions/therapy*
		                        			;
		                        		
		                        			Singapore
		                        			;
		                        		
		                        			Stomach Neoplasms/therapy*
		                        			
		                        		
		                        	
9.Response to letters arising from publication of the Academy of Medicine, Singapore clinical guideline on the use of sedation by non-anaesthesiologists during gastrointestinal endoscopy in the hospital setting.
Tiing Leong ANG ; Yaw Chong GOH ; Khoon Lin LING
Annals of the Academy of Medicine, Singapore 2022;51(7):452-453
10.Clinical guidance on endoscopic management of colonic polyps in Singapore.
Tiing Leong ANG ; Jit Fong LIM ; Tju Siang CHUA ; Kok Yang TAN ; James Weiquan LI ; Chern Hao CHONG ; Kok Ann GWEE ; Vikneswaran S/O NAMASIVAYAM ; Charles Kien Fong VU ; Christopher Jen Lock KHOR ; Lai Mun WANG ; Khay Guan YEOH
Singapore medical journal 2022;63(4):173-186
		                        		
		                        			
		                        			Colonoscopy with endoscopic resection of detected colonic adenomas interrupts the adenoma-carcinoma sequence and reduces the incidence of colorectal cancer and cancer-related mortality. In the past decade, there have been significant developments in instruments and techniques for endoscopic polypectomy. Guidelines have been formulated by various professional bodies in Europe, Japan and the United States, but some of the recommendations differ between the various bodies. An expert professional workgroup under the auspices of the Academy of Medicine, Singapore, was set up to provide guidance on the endoscopic management of colonic polyps in Singapore. A total of 23 recommendations addressed the following issues: accurate description and diagnostic evaluation of detected polyps; techniques to reduce the risk of post-polypectomy bleeding and delayed perforation; the role of specific endoscopic resection techniques; the histopathological criteria for defining endoscopic cure; and the role of surveillance colonoscopy following curative resection.
		                        		
		                        		
		                        		
		                        			Adenoma/surgery*
		                        			;
		                        		
		                        			Colonic Neoplasms/surgery*
		                        			;
		                        		
		                        			Colonic Polyps/surgery*
		                        			;
		                        		
		                        			Colonoscopy/methods*
		                        			;
		                        		
		                        			Colorectal Neoplasms/pathology*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Singapore
		                        			;
		                        		
		                        			United States
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail